Antidepressants in the Treatment of Chronic Pain

Mechanism of action

The central analgesic mechanism is the descending modulation of pain. The central nervous system has inhibitory pathways that descend from the midbrain (periaqueductal gray, PAG) to the rostroventral medulla (RVM) and from there to the spinal dorsal horn, where they silence nociceptive signals before they ascend to the córtex. Serotonin and norepinephrine are the main neurotransmitters of this pathway. Tricyclics and SNRIs increase the availability of these neurotransmitters in the synaptic cleft — the result: more active descending pathways and less intense pain.

Tricyclics add two relevant secondary effects: blockade of sodium channels (useful in neuropathic pain, in the way anticonvulsants act) and partial NMDA antagonism (modulation of central sensitization). This explains why amitriptyline maintains strong efficacy in neuropathic pain even when compared to more modern molecules. Duloxetine and venlafaxine have a narrower profile — without sodium or NMDA blockade — but are better tolerated in many patients. When pain and depression coexist (a very common situation in chronic pain), the additional antidepressant effect is a benefit — but it is not a necessary condition for the analgesic effect to appear.

Scientific evidence

The evidence on antidepressants in pain is among the most consistent in modern pain medicine — and clearly distinguishes which molecules work in which conditions. The popular error is to treat "antidepressants" as a homogeneous block; the differences among tricyclics, SNRIs, and SSRIs are clinically and pharmacologically decisive.

The Cochrane review by Moore et al. (2015) on amitriptyline in neuropathic pain synthesized dozens of trials and consolidated NNT around 4-6 for clinically relevant relief — a robust threshold for an oral analgesic. The Cochrane review by Lunn et al. (2014) established duloxetine as first line in painful diabetic neuropathy, with consistent efficacy and tolerability superior to tricyclics in many patients. In fibromyalgia, Busch et al. (Cochrane 2017) and the EULAR guideline include duloxetine among the pharmacological options with the strongest support, paired with structured exercise.

In neuropathic pain in the broad sense, the guideline by Finnerup et al. (Lancet Neurology 2015) positions tricyclics (amitriptyline, nortriptyline) and SNRIs (duloxetine, venlafaxine) as first line, alongside anticonvulsants (gabapentin, pregabalin). In migraine prophylaxis, amitriptyline has been recommended for decades with consistent support — the review by Silberstein (Cephalalgia) and subsequent guidelines maintain the indication. In chronic musculoskeletal pain, duloxetine is FDA-approved for chronic low back pain and osteoarthritis, with meta-analyses showing modest but consistent gains in pain and function.

By contrast, trials with SSRIs (fluoxetine, sertraline, escitalopram) in pain alone — neuropathic or fibromyalgia — consistently fail to show meaningful analgesic benefit. The biological explanation is direct: SSRIs increase serotonin but not norepinephrine, and descending modulation of pain requires both. This does not mean that SSRIs have no role in patients with chronic pain — when significant depression or anxiety coexist, psychiatric treatment indirectly improves the suffering associated with pain. But the effect is on mood, not directly on pain.

Indications

Evidence-based indications are condition-specific — not "chronic pain in general". Choosing the right antidepressant for the right condition is what separates rational use from generic prescription.

How they are used

Three principles guide rational use: slow titration from a low dose, clinical patience because the effect takes 2-6 weeks, and analgesic doses typically lower than psychiatric ones. Premature discontinuation for "not working" is one of the main causes of apparent therapeutic failure — patient education about expectations is itself a clinical intervention.

Titrating analgesic antidepressants: start low (amitriptyline 10-25 mg at night) and increase gradually based on tolerance and clinical response

Fig. · placeholder

Antidepressants used in pain — by generic name

Availability is broad in most markets. Amitriptyline and nortriptyline have established generics and are widely covered — the monthly cost is low, which favors adherence in populations with financial constraints. Duloxetine has variable insurance coverage and broad out-of-pocket availability. Venlafaxine coverage varies. All listed items require medical prescription.

A practical note on cost and adherence: the generic amitriptyline costs a fraction of the price of newer alternatives, and in many cases of neuropathic pain and fibromyalgia provides comparable efficacy. In patients with a favorable profile (no cardiac contraindications, no closed-angle glaucoma, no significant prostatic hypertrophy), starting with amitriptyline is a rational decision — if tolerance is limited, consider nortriptyline or move to duloxetine. Continued use requires periodic reassessment.

Dosing, interactions, and special populations

Elderly. Prefer nortriptyline over amitriptyline — less anticholinergic, therefore lower risk of constipation, urinary retention, and confusion. Baseline ECG recommended in all patients starting a tricyclic after age 60. With SNRI use, attention to risk of hyponatremia (SIADH), especially in the first weeks.

Cardiac disease. Baseline ECG mandatory when starting a tricyclic — there is risk of QT interval prolongation and arrhythmias. Avoid in ventricular arrhythmia, recent MI, or significant conduction blocks.

Closed-angle glaucoma. Tricyclics are contraindicated due to the anticholinergic effect on the iridocorneal angle. In open-angle glaucoma, use may be acceptable with ophthalmologic evaluation.

Pregnant patients. Amitriptyline is generally considered acceptable when needed; paroxetine should be avoided if an SSRI is the choice (signal of cardiac malformation). Duloxetine has more limited data — shared decision with the obstetrician.

Lactating mothers. Amitriptyline and duloxetine have reasonable data in breastfeeding, with relatively low milk excretion. Discuss with the obstetrician and pediatrician before starting in a lactating mother.

Adverse effects, risks, and contraindications

The risk profile of antidepressants in pain is molecule-specific — tricyclics, SNRIs, and SSRIs have different profiles. Most adverse effects are dose-dependent and improve with slow titration, but some require specific attention.

Important contraindications. Tricyclics: hypersensitivity; recent MI, ventricular arrhythmia, or significant bundle branch block; closed-angle glaucoma; prostatic hypertrophy with retention; concomitant MAOI use. Duloxetine: significant hepatopathy, untreated closed-angle glaucoma, severe renal failure (CrCl < 30 mL/min). Venlafaxine: uncontrolled hypertension is a strong precaution. All: MAOI use concomitant or within the past 2 weeks (washout).

Limitations and what is not yet known

Antidepressants in pain are one of the classes with the best evidence profile and lowest cost barrier — but they face clinical limitations and, above all, stigma that reduces adherence. Separating what we know from what we still do not know is an essential part of the conversation with the patient.

Evidence Gaps

Time to effect drives premature discontinuations. The patient expects an effect in days (as with NSAIDs) and, when no improvement is felt in 1-2 weeks, stops. The analgesic effect takes 2-6 weeks to be fully established — patient education about this expectation is a clinical intervention and, when done well, substantially increases adherence.

Tolerability limits a portion of patients. Between 20-30% of patients who start amitriptyline or duloxetine discontinue due to adverse effects — nausea, sedation, weight gain, anticholinergic effects. Slow titration substantially reduces these problems, but does not remove them entirely. In those who do not tolerate the first option, the switch between tricyclic and SNRI (or vice versa) often allows the class to be maintained.

Stigma is still a significant barrier. The public confusion between "antidepressant" and "psychiatric medication for those with depression" leads patients to resist the prescription or stop in silence. The clinical work of explaining why the medication was prescribed — modulation of pain, lower analgesic doses — is usually decisive for adherence.

Long-term data are limited. The majority of trials cover 8-12 weeks. Effect with continued use for > 2 years, impact on cognitive function in elderly patients on prolonged therapy, and ideal strategies for discontinuation and reinitiation remain áreas with partial data — individualized management with periodic reassessments is the reasonable standard.

Relationship with medical acupuncture

Antidepressants and medical acupuncture act on distinct mechanisms — the former on neurotransmitters of descending modulation (serotonin, norepinephrine), acupuncture on local and central neuromodulation (periaqueductal gray matter, endogenous opioids, autonomic modulation). No pharmacological interactions have been described, which allows combination in a plan coordinated by the physician. The detailed comparison, including integrated strategies and specific meta-analyses, is in Amitriptyline + Duloxetine vs Acupuncture. The practical logic: in some cases, the two can complement each other — in some intolerant patients, the addition of acupuncture may contribute to pain management, but any adjustment or discontinuation of the antidepressant is a medical decision and must follow gradual taper when indicated.

When to seek medical care

Use of an antidepressant in pain always involves medical follow-up — for the class, for titration, for interactions, and for risk populations. Some signs require early contact and others represent a clinical emergency.